Crystalline Compound I Form F Synthesis
Example 10
Compound I Form F was obtained via slurry of Compound I calcium salt hydrate Form A in MEK at room temperature.
A. X-Ray Powder Diffraction
XRPD was performed with a Panalytical X'Pert3 Powder XRPD on a Si zero-background holder. The 20 position was calibrated against a Panalytical Si reference standard disc. The XRPD diffractogram for Compound I Form F is shown in FIG. 16 and summarized in Table 21.
TABLE 21
XRPD signals for crystalline Compound I Form F
Angle (degrees
XRPD Peaks2-Theta ± 0.2)Intensity %
19.14100.0
29.0689.3
35.348.5
47.548.2
510.623.7
611.918.5
Compound I Form F is characterized by the following elemental analysis Table:
CompoundCompound
Batch #CaI:Ca ratioNaI:Na ratio
114%1:25%1:1
2 7%1:13%1:0.8
Free full text:
Click here
US11873300B2. Crystalline forms of CFTR modulators (2024-01-16). Vertex Pharmaceuticals Incorporated [US]. Inventors: Yi Shi [US], Kevin J. Gagnon [US], Jicong Li [US], Jennifer Lu [US], Ales Medek [US], Muna Shrestha [US], Michael Waldo [US], Beili Zhang [US], Carl L. Zwicker [US], Corey Don Anderson [US], Jeremy J. Clemens [US], Thomas Cleveland [US], Timothy Richard Coon [US], Bryan Frieman [US], Peter Grootenhuis [US], Sara Sabina Hadida Ruah [US], Jason McCartney [US], Mark Thomas Miller [US], Prasuna Paraselli [US], Fabrice Pierre [US], Sara E. Swift [US], Jinglan Zhou [US].